Evidence map›Paper›PMID 37552302›Full record

ArticleJAMA2023

Sugar-Sweetened and Artificially Sweetened Beverages and Risk of Liver Cancer and Chronic Liver Disease Mortality.

Longgang Zhao, Xinyuan Zhang, Mace Coday, David O Garcia, Xinyi Li, Yasmin Mossavar-Rahmani, Michelle J Naughton, Melissa Lopez-Pentecost, Nazmus Saquib, Aladdin H Shadyab and 12 more

Open access · greenAbstract readComparative Study
In one paragraph

Article in JAMA, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 3 pooled it
15.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 13 institutions in 2 countries.

Longgang ZhaoDepartment of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia.
Xinyuan ZhangChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Mace CodayDepartment of Preventive Medicine, University of Tennessee Health Science Center, Memphis.
David O GarciaDepartment of Health Promotion Sciences, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson.
Xinyi LiDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Yasmin Mossavar-RahmaniDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.
Michelle J NaughtonDivision of Cancer Prevention and Control, College of Medicine, The Ohio State University, Columbus.
Melissa Lopez-PentecostClinical Translational Sciences, College of Medicine, University of Arizona, Tucson.
Nazmus SaquibCollege of Medicine, Sulaiman Alrajhi University, Bukariyah, Qassim, Saudi Arabia.
Aladdin H ShadyabHerbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla.
Michael S SimonPopulation Studies and Prevention Program, Karmanos Cancer Institute at Wayne State University, Detroit, Michigan.
Linda G SnetselaarDepartment of Epidemiology, College of Public Health, University of Iowa, Iowa City.
Fred K TabungDepartment of Internal Medicine, College of Medicine and Comprehensive Cancer Center-James Cancer Hospital, Solove Research Institute, The Ohio State University, Columbus.
Deirdre K TobiasDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Trang VoPhamEpidemiology Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Katherine A McGlynnDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
Howard D SessoDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Edward GiovannucciDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
JoAnn E MansonDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Frank B HuDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Lesley F TinkerDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Xuehong ZhangChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Harvard University · USThe Ohio State University · USUniversity of Arizona · USAlbert Einstein College of Medicine · USBrigham and Women's Hospital · USDivision of Cancer Epidemiology and GeneticsFred Hutch Cancer Center · USSulaiman Al Rajhi Colleges · SAThe Barbara Ann Karmanos Cancer Institute · USUniversity of California, San Diego · USUniversity of Iowa · USUniversity of Tennessee Health Science Center · USUniversity of Washington · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0M
Studies of Rare CancersZIACP010158 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MCGLYNN, KATHERINE · 2009 to 2025
$19.1M
Decoding mechanisms underlying metabolic dysregulation in obesity and digestive cancer riskU01CA272452 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI GIOVANNUCCI, EDWARD, TOBIAS, DEIRDRE KAY · 2022 to 2025
$6.4M
Perfluoroalkyl Substances (PFASs) and Liver Cancer Risk in the United StatesU01CA259208 · NCI · YALE UNIVERSITY · PI ZHANG, XUEHONG · 2022 to 2025
$2.9M
University of Arizona's Initiative for Maximizing Student Development (IMSD)T32GM139779 · NIGMS · UNIVERSITY OF ARIZONA · PI FRANS E TAX · 2022 to 2026
$2.9M
Helicobacter Infection and Liver Cancer Risk among African Americans andWhites in the United StatesR37CA262299 · NCI · YALE UNIVERSITY · PI Xuehong Zhang · 2021 to 2026
$2.4M
Multidisciplinary Study of Folate Intake and Colorectal CancerR21CA252962 · NCI · YALE UNIVERSITY · PI ZHANG, XUEHONG · 2021 to 2022
$487k
Proteomics Study of Non-viral Related Hepatocellular Carcinoma RiskR21CA238651 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ZHANG, XUEHONG · 2020 to 2021
$477k
NCI NIH HHS P30 CA086862NCI NIH HHS R21 CA238651NCI NIH HHS R21 CA252962NCI NIH HHS R37 CA262299NCI NIH HHS U01 CA259208NCI NIH HHS U01 CA272452NIGMS NIH HHS T32 GM139779
6 · The paper itself

Abstract

Importance: Approximately 65% of adults in the US consume sugar-sweetened beverages daily. Objective: To study the associations between intake of sugar-sweetened beverages, artificially sweetened beverages, and incidence of liver cancer and chronic liver disease mortality. Design, Setting, and Participants: A prospective cohort with 98 786 postmenopausal women aged 50 to 79 years enrolled in the Women's Health Initiative from 1993 to 1998 at 40 clinical centers in the US and were followed up to March 1, 2020. Exposures: Sugar-sweetened beverage intake was assessed based on a food frequency questionnaire administered at baseline and defined as the sum of regular soft drinks and fruit drinks (not including fruit juice); artificially sweetened beverage intake was measured at 3-year follow-up. Main Outcomes and Measures: The primary outcomes were (1) liver cancer incidence, and (2) mortality due to chronic liver disease, defined as death from nonalcoholic fatty liver disease, liver fibrosis, cirrhosis, alcoholic liver diseases, and chronic hepatitis. Cox proportional hazards regression models were used to estimate multivariable hazard ratios (HRs) and 95% CIs for liver cancer incidence and for chronic liver disease mortality, adjusting for potential confounders including demographics and lifestyle factors. Results: During a median follow-up of 20.9 years, 207 women developed liver cancer and 148 died from chronic liver disease. At baseline, 6.8% of women consumed 1 or more sugar-sweetened beverage servings per day, and 13.1% consumed 1 or more artificially sweetened beverage servings per day at 3-year follow-up. Compared with intake of 3 or fewer servings of sugar-sweetened beverages per month, those who consumed 1 or more servings per day had a significantly higher risk of liver cancer (18.0 vs 10.3 per 100 000 person-years [P value for trend = .02]; adjusted HR, 1.85 [95% CI, 1.16-2.96]; P = .01) and chronic liver disease mortality (17.7 vs 7.1 per 100 000 person-years [P value for trend <.001]; adjusted HR, 1.68 [95% CI, 1.03-2.75]; P = .04). Compared with intake of 3 or fewer artificially sweetened beverages per month, individuals who consumed 1 or more artificially sweetened beverages per day did not have significantly increased incidence of liver cancer (11.8 vs 10.2 per 100 000 person-years [P value for trend = .70]; adjusted HR, 1.17 [95% CI, 0.70-1.94]; P = .55) or chronic liver disease mortality (7.1 vs 5.3 per 100 000 person-years [P value for trend = .32]; adjusted HR, 0.95 [95% CI, 0.49-1.84]; P = .88). Conclusions and Relevance: In postmenopausal women, compared with consuming 3 or fewer servings of sugar-sweetened beverages per month, those who consumed 1 or more sugar-sweetened beverages per day had a higher incidence of liver cancer and death from chronic liver disease. Future studies should confirm these findings and identify the biological pathways of these associations.

Indexed as

Artificially Sweetened BeveragesLiver NeoplasmsSugar-Sweetened BeveragesAgedBeveragesCarbonated BeveragesChronic DiseaseFemaleHumansLiver CirrhosisLiver DiseasesMiddle AgedNon-alcoholic Fatty Liver DiseaseProspective StudiesRisk FactorsSugarsSugarsSweetening Agents

Identifiers

PMID37552302
PMCPMC10410478
OpenAlexW4385658221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.